Asset Details
Do you wish to reserve the book?
Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
Do you wish to request the book?
Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
2019
Overview
Pegaspargase (Oncaspar
®
), a pegylated form of native
Escherichia coli
-derived
l
-asparaginase (hereafter referred as
E. coli
l
-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Relative to
E. coli
l
-asparaginase, pegaspargase has a prolonged circulation time, thereby offering less frequent administration. Moreover, pegylation of
E. coli
l
-asparaginase may diminish the immunogenicity of the enzyme. Based on extensive evidence, intramuscular (IM) or intravenous (IV) administration of pegaspargase as a component of a multi-agent chemotherapy is an effective first-line treatment for paediatric and adult patients with ALL, as well as for the treatment of paediatric and adult patients with ALL and hypersensitivity to
E. coli
l
-asparaginase. Pegaspargase had a manageable tolerability profile in paediatric and adult patients with newly diagnosed ALL, with the most commonly occurring adverse events being generally consistent to that seen with
E. coli
l
-asparaginase. Pegaspargase treatment in patients with relapsed ALL and hypersensitivity to
E. coli
l
-asparaginase had a similar tolerability profile to that observed in patients with newly diagnosed ALL. Given the potentially reduced immunogenicity and more convenient dosage regimen over
E. coli
l
-asparaginase, pegaspargase remains an important and effective treatment option for paediatric and adult patients with ALL, including those with hypersensitivity to
E. coli
l
-asparaginase.
